Karyopharm Therapeutics, Inc. (KPTI)
0.3901
+0.04
(+11.20%)
USD |
NASDAQ |
Oct 16, 16:00
0.3915
0.00 (0.00%)
After-Hours: 20:00
Karyopharm Therapeutics Free Cash Flow : -65.35M for June 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | -65.35M |
| March 31, 2026 | -59.11M |
| December 31, 2025 | -75.37M |
| September 30, 2025 | -89.30M |
| June 30, 2025 | -102.89M |
| March 31, 2025 | -122.69M |
| December 31, 2024 | -127.63M |
| September 30, 2024 | -120.46M |
| June 30, 2024 | -130.53M |
| March 31, 2024 | -117.73M |
| December 31, 2023 | -92.72M |
| September 30, 2023 | -100.98M |
| June 30, 2023 | -99.86M |
| March 31, 2023 | -109.31M |
| December 31, 2022 | -149.67M |
| September 30, 2022 | -97.06M |
| June 30, 2022 | -98.61M |
| March 31, 2022 | -119.22M |
| December 31, 2021 | -112.83M |
| September 30, 2021 | -169.35M |
| June 30, 2021 | -183.70M |
| March 31, 2021 | -168.25M |
| December 31, 2020 | -160.38M |
| September 30, 2020 | -169.16M |
| June 30, 2020 | -161.47M |
| Date | Value |
|---|---|
| March 31, 2020 | -169.38M |
| December 31, 2019 | -191.03M |
| September 30, 2019 | -200.75M |
| June 30, 2019 | -203.30M |
| March 31, 2019 | -193.12M |
| December 31, 2018 | -161.48M |
| September 30, 2018 | -117.81M |
| June 30, 2018 | -100.41M |
| March 31, 2018 | -84.10M |
| December 31, 2017 | -73.78M |
| September 30, 2017 | -88.21M |
| June 30, 2017 | -86.79M |
| March 31, 2017 | -85.96M |
| December 31, 2016 | -84.46M |
| September 30, 2016 | -85.32M |
| June 30, 2016 | -90.45M |
| March 31, 2016 | -98.25M |
| December 31, 2015 | -95.44M |
| September 30, 2015 | -87.43M |
| June 30, 2015 | -80.48M |
| March 31, 2015 | -63.99M |
| December 31, 2014 | -54.28M |
| September 30, 2014 | -51.52M |
| June 30, 2014 | -41.93M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| Madrigal Pharmaceuticals, Inc. | -209.28M |
| Relay Therapeutics, Inc. | -212.20M |
| ACADIA Pharmaceuticals, Inc. | 145.62M |
| Alnylam Pharmaceuticals, Inc. | 793.94M |
| Anika Therapeutics, Inc. | 0.562M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -24.93M |
| Cash from Investing (Quarterly) | -10.04M |
| Cash from Financing (Quarterly) | -0.898M |
| Free Cash Flow Per Share (Quarterly) | -0.8615 |
| Free Cash Flow to Equity (Quarterly) | -50.25M |
| Free Cash Flow to Firm (Quarterly) | -11.79M |
| Free Cash Flow Yield | -835.2% |